Stabilis

Glycopyrronium bromide



Noms commerciaux

Glycopyrronium bromide injection	Grande Bretagne
Robinul	Autriche, Belgique, Etats Unis d'Amérique, Finlande, Norvège, Suède

Stabilité des solutions

PP	∅	0,2 mg/ml	25°C		90			1756
PP	∅	0,2 mg/ml	4°C		90			1756

Stabilité en mélange

	∅	0,1 mg/ml	25°C	?	Palonosetron hydrochloride : 25 µg/ml	4	2286
PVC	▲	15 mg/ml	21°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PVC	▲	15 mg/ml	36°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	9	2113
PVC	▲	15 mg/ml	4°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PP	▲	15 mg/ml	21°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PP	▲	0,1 mg/ml	23°C		Ondansetron hydrochloride : 1 mg/ml	24	815
PP	▲	15 mg/ml	36°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	16	2113
PP	▲	15 mg/ml	4°C		Haloperidol lactate : 52 mg/ml Buprenorphine hydrochloride : 57 mg/ml	30	2113
PP	▲	0,1 mg/ml	4°C		Ondansetron hydrochloride : 1 mg/ml	24	815

Compatibilités

		Glycopyrronium bromide Butorphanol tartrate		3599
		Glycopyrronium bromide : 0.2 mg/ml Cimetidine hydrochloride : 150 mg/ml		1438
		Glycopyrronium bromide Dexamethasone sodium phosphate		3668
		Glycopyrronium bromide Diazepam		3599
		Glycopyrronium bromide Dimenhydrinate		3599
		Glycopyrronium bromide Droperidol		3599
		Glycopyrronium bromide Fentanyl citrate		3599
		Glycopyrronium bromide Lorazepam		3599
		Glycopyrronium bromide Methohexital sodium		3599
		Glycopyrronium bromide : 0.1 mg/ml Midazolam hydrochloride : 2.5 mg/ml	∅	404
		Glycopyrronium bromide Morphine sulfate		3599
		Glycopyrronium bromide Neostigmine methylsulfate		3599
		Glycopyrronium bromide : 0,2 mg/ml Neostigmine methylsulfate : 0,5 mg/ml	∅	2286
		Glycopyrronium bromide : 0.1 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	815
		Glycopyrronium bromide : 0.07 & 0.11 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml	●	2900
		Glycopyrronium bromide : 0.07 & 0.11 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml	▲	2900
		Glycopyrronium bromide : 0,2 mg/ml Palonosetron hydrochloride : 50 µg/ml	∅	2286
		Glycopyrronium bromide Pentobarbital sodium		3599
		Glycopyrronium bromide Pethidine hydrochloride		3599
		Glycopyrronium bromide Promethazine hydrochloride		3599
		Glycopyrronium bromide : 0.2 mg/ml Propofol		660
		Glycopyrronium bromide : 0.2 mg/ml Propofol : 10 mg/ml	∅	300
		Glycopyrronium bromide : 0,2 mg/ml Ranitidine hydrochloride : 25 mg/ml	∅	58
		Glycopyrronium bromide : 0,2 mg/ml Rocuronium bromide : 10 mg/ml		4828

	Glycopyrronium bromide Thiopental sodium		3599

Voie d'administration



Bibliographie

	Type	Source
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
1438	Revue	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1756	Revue	Storms ML, Stewart JT, Flynn WW. Stability of glycopyrrolate injection at ambient temperature and 4°C in polypropylene syringes. Int J Pharm Compound 2003 ; 7: 65-67.
2113	Revue	Jäppinen A, Kokki H, Naaranlahti TJ, Rasi AS. Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharm World Sci 1999 ; 21, 6: 272-274.
2286	Revue	Ben M, Trusley C, Kupiec TC, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 4: 368-371.
2900	Revue	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3599	Laboratoire	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013
3668	Laboratoire	Dexamethasone - Summary of Product Characteristics Hospira 2015

4828	Revue	Weeks A.L, Sotos J, Woolsey B, Johnston W.M, Cornelius B.W. The Physical Compatibility of Glycopyrrolate and Rocuronium. Anesth Prog 2023 ;70(2):53-57.

Stabilis

Glycopyrronium bromide



Stabilité des préparations

50 mg ®=?	Horizon pharmaceutical	Eau du robinet 100 ml	24-26°C		25				2833
	10 mg ® = ?	SyrSpend SF® >> 20 ml	25°C	?	90				4198
	10 mg ® = ?	SyrSpend SF® >> 20 ml	4°C	?	90				4198
	30 mg ® = ? (Corepharma)	OraPlus® / OraSweet® (1:1) >> 60 ml	23-25°C		90				3203
	30 mg ® = ? (Corepharma)	OraPlus® / OraSweet SF® (1:1) >> 60 ml	23-25°C		90				3203
	20 mg ® = ?	OraPlus® / OraSweet® (1:1) >> 100 ml	25°C		14				3856
	20 mg ® = ?	Methylcellulose 1% / Sirop simple (1:10) >> 100 ml	25°C		14				3856
	20 mg ® = ?	OraPlus® / OraSweet® (1:1) >> 100 ml	4°C		14				3856
	20 mg ® = ?	Methylcellulose 1% / Sirop simple (1:10) >> 100 ml	4°C		14				3856
?	50 mg	Sorbitol 10 g Tampon phosphate 0.05M pH 5.6 >> 100 ml	24-26°C		129				2834
?	50 mg	Saccharose 10 g Tampon phosphate 0.05M pH 5.6 >> 100 ml	24-26°C		129				2834

Facteur influençant la stabilité

	pH < 6				2833
	pH = 7				2834

Bibliographie

	Type	Source
2833	Revue	Das Gupta V. Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets Int J Pharm Compound 2001 ; 5, 6: 480-481.
2834	Revue	Das Gupta V. Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared With the Use of Powder Int J Pharm Compound 2003 ; 7, 5: 386-388.
3203	Revue	Cober MP, Johnson CE, Sudekum D, Penprase K Stability of extemporaneously prepared glycopyrrolate oral suspensions. Am J Health-Syst Pharm 2011 ; 68:843-845.
3856	Revue	Nahata M.C. Long-term Stability of Zonisamide, Amitriptyline, and Glycopyrrolate in Extemporaneously Prepared Liquid-dosage Forms at Two Temperatures Int J Pharm Compound 2016 ; 20, 2:164-166.
4198	Revue	Uriel M, Gomez-Rincon C, Marro D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. Pharmazie 2018 73;196-201

Dictionnaire

	Antimuscarinique		injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Seringue polypropylène
	Aucun		Lumière
	Jour		A l'abri de la lumière
	Stabilité en mélange		Solvant
	Molécule		Verre
	Non précisée		Heure
	Polyvinyl chlorure		Chlorure de sodium 0,9%
	Polypropylène		Compatibilités
	Compatible		Incompatibilité non précisée
	Incompatible		Eau pour préparation injectable
	Instabilité de l'émulsion à 4 heures		Voie d'administration
	Intraveineuse		Intramusculaire
	Sous cutanée		Perfusion SC continue
	Bibliographie		Solution buvable
	Stabilité des préparations		Origine
	Excipient		Comprimés
	Poudre		Flacon plastique
	Non précisé		Facteur influençant la stabilité
	Provoque		Augmentation stabilité
	Dégradation		Dictionnaire